Evidence map›Paper›PMID 39178368›Full record

ArticleJCO precision oncology2024

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.

Laura S Graham, Nicholas C Henderson, Olesia Kellezi, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Deepak Kilari, Michael Pierro, Bicky Thapa, Abhishek Tripathi and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Laura S GrahamUniversity of Colorado, Aurora, CO.ORCID 0000-0003-4371-572X
Nicholas C HendersonUniversity of Michigan, Ann Arbor, MI.ORCID 0000-0003-3184-0945
Olesia KelleziUniversity of Michigan, Ann Arbor, MI.ORCID 0000-0002-9769-3258
Clara HwangDivision of Hematology/Oncology, Department of Internal Medicine, Henry Ford Cancer Institute, Detroit, MI.ORCID 0000-0002-0998-323X
Pedro C BarataUniversity Hospitals Seidman Cancer Center, Cleveland, OH.ORCID 0000-0002-8890-2951
Mehmet A BilenWinship Cancer Institute of Emory University, Atlanta, GA.ORCID 0000-0003-4003-1103
Deepak KilariDepartment of Medicine, Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI.
Michael PierroDepartment of Medicine, Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0003-1047-7614
Bicky ThapaDepartment of Medicine, Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0002-7636-8907
Abhishek TripathiStephenson Cancer Center, Oklahoma City, OK.ORCID 0000-0002-5198-0673
George MoUniversity of Washington/Fred Hutchinson Cancer Center, Seattle, WA.
Matthew LabriolaDivision of Medical Oncology, Duke University Medical Center, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC.ORCID 0000-0003-0919-9864
Joseph J ParkDivision of Medical Oncology, Duke University Medical Center, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC.
Shoshana RothsteinKarmanos Cancer Institute, Wayne State University, Detroit, MI.
Rohan GarjeMiami Cancer Institute, Baptist Health South Florida, Miami, FL.ORCID 0000-0002-7244-5602
Vadim S KoshkinDivision of Hematology and Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-2277-8668
Vaibhav G PatelTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Tanya DorffDepartment of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.ORCID 0000-0001-5990-298X
Andrew J ArmstrongDivision of Medical Oncology, Duke University Medical Center, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC.ORCID 0000-0001-7012-1754
Rana R McKayMoores Cancer Center, University of California San Diego, La Jolla, CA.ORCID 0000-0002-0581-7963
Ajjai AlvaUniversity of Michigan, Ann Arbor, MI.
Michael T SchweizerUniversity of Washington/Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-5510-0661

Funding

Paul Calabresis Award in Clinical Oncology ResearchK12CA086913 · NCI · UNIVERSITY OF COLORADO DENVER · PI VIRGINIA F. BORGES, Jill E Slansky · 2000 to 2026
$17.8M
NCI NIH HHS K12 CA086913
6 · The paper itself

Abstract

purposeOutcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non-

methodsRetrospective data from the PROMISE consortium were used. Clinical outcomes differences were assessed between patients with

resultsOne hundred and forty-six patients received PARPi (cohort A: 94, cohort B: 45, cohort C: 7) and 104 received platinum chemotherapy (cohort A: 48, cohort B: 44, cohort C: 10). PSA50 response rate to PARPi was higher in cohort A (61%) than cohort B (5%),

conclusionPatients with

Indexed as

Poly(ADP-ribose) Polymerase InhibitorsProstatic NeoplasmsRecombinational DNA RepairAgedAged, 80 and overDNA DamageHumansMaleMiddle AgedMutationRetrospective StudiesPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID39178368
PMCPMC11346579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.